Quick Answer
IMMUCELL CORP /DE/ reported R&D Expense of $3.04 million for fiscal year 2025.
IMMUCELL CORP /DE/ R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.04M | -22.0% |
| 2024 | $3.90M | -11.3% |
| 2023 | $4.39M | -2.2% |
| 2022 | $4.49M | +7.8% |
| 2021 | $4.17M | -4.3% |
| 2020 | $4.35M | +18.1% |
| 2019 | $3.69M | +4.9% |
| 2018 | $3.52M | +71.8% |
| 2017 | $2.05M | +64.5% |
| 2016 | $1.24M | +0.7% |
| 2015 | $1.24M | -43.3% |
| 2014 | $2.18M | +88.8% |
| 2013 | $1.15M | +25.8% |
| 2012 | $917.6K | -46.7% |
| 2011 | $1.72M | +15.2% |
| 2010 | $1.49M | -9.2% |
| 2009 | $1.64M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $694.3K | -11.7% | -16.5% |
| June 30, 2025 | $831.9K | -19.3% | +9.9% |
| March 31, 2025 | $756.8K | -40.1% | -3.7% |
| September 30, 2024 | $786.1K | -29.7% | -23.7% |
| June 30, 2024 | $1.03M | -6.3% | -18.4% |
| March 31, 2024 | $1.26M | +13.7% | +12.9% |
| September 30, 2023 | $1.12M | -11.9% | +1.7% |
| June 30, 2023 | $1.10M | -3.4% | -1.0% |
- IMMUCELL CORP /DE/ showed a decrease of -22.0% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, IMMUCELL CORP /DE/’s r&d expense has grown by 84.9% (from $1.64 million to $3.04 million).
- The most recent figure is from IMMUCELL CORP /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: